You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRemoxipride
Accession NumberDB00409  (APRD00316)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionAn antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem]
Structure
Thumb
Synonyms
a-33547
FLA-731
Remoxiprida
Remoxipride
Remoxipridum
Romoxipride
Roxiam
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0223RD59PE
CAS number80125-14-0
WeightAverage: 371.269
Monoisotopic: 370.089205259
Chemical FormulaC16H23BrN2O3
InChI KeyGUJRSXAPGDDABA-NSHDSACASA-N
InChI
InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
IUPAC Name
3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide
SMILES
CCN1CCC[[email protected]]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC
Pharmacology
IndicationRemoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.
Structured Indications Not Available
PharmacodynamicsRemoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.
Mechanism of actionRemoxipride acts as an antagonist at the D2 dopamine receptor. It is believed that overactivity of dopamine systems in the mesolimbic pathway may contribute to the "positive symptoms" of schizophrenia (such as delusions and hallucinations), whereas problems with dopamine function in the mesocortical pathway may be responsible for the "negative symptoms", such as avolition, flat emotional response and alogia. Therefore, by decreasing the levels of dopamine in these pathways, it is thought that remoxipride is able to reduce the symptoms of schizophrenia, particularily the "positive symptoms".
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
5-hydroxytryptamine receptor 2AProteinunknown
other/unknown
HumanP28223 details
Sigma non-opioid intracellular receptor 1Proteinunknown
antagonist
HumanQ99720 details
Related Articles
AbsorptionRapidly absorbed. Absolute bioavailability is 90%.
Volume of distributionNot Available
Protein binding89-98%
Metabolism

No active metabolites

Route of eliminationNot Available
Half life4-7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Remoxipride is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineRemoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineRemoxipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineRemoxipride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineRemoxipride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Remoxipride can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Remoxipride is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alfentanil.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Remoxipride.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remoxipride.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Remoxipride can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amperozide.Experimental
AmphetamineRemoxipride may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Remoxipride can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Asenapine.Approved
AtomoxetineThe metabolism of Remoxipride can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Azaperone.Vet Approved
AzelastineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzocaine.Approved
BenzphetamineRemoxipride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Remoxipride can be decreased when combined with Betaxolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride.Approved, Investigational
BuprenorphineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Remoxipride can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Remoxipride.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Remoxipride can be decreased when combined with Celecoxib.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Remoxipride can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorphenamine.Approved
ChlorphentermineRemoxipride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Remoxipride can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Remoxipride can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Remoxipride can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Remoxipride can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Remoxipride can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Remoxipride can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clidinium.Approved
ClobazamThe metabolism of Remoxipride can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Remoxipride can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Remoxipride can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Remoxipride can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Remoxipride can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Remoxipride can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Remoxipride.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Remoxipride can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Remoxipride can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Remoxipride can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Remoxipride is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desflurane.Approved
DesipramineThe metabolism of Remoxipride can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Remoxipride.Approved
DetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineRemoxipride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Remoxipride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diazepam.Approved, Illicit, Vet Approved
DiethylpropionRemoxipride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Remoxipride can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Remoxipride is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Illicit
DronedaroneThe metabolism of Remoxipride can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Remoxipride can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Remoxipride is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Remoxipride.Approved, Investigational
EliglustatThe metabolism of Remoxipride can be decreased when combined with Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Remoxipride.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Remoxipride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Remoxipride.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remoxipride.Approved
EthanolRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Remoxipride can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Remoxipride can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Remoxipride.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Remoxipride is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Remoxipride can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hexobarbital.Approved
HydrocodoneRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride.Approved, Illicit
Hydroxyamphetamine hydrobromideRemoxipride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Iloperidone.Approved
ImipramineThe metabolism of Remoxipride can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Remoxipride can be decreased when combined with Indinavir.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remoxipride.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Remoxipride can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Remoxipride can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Remoxipride.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Remoxipride.Approved, Investigational
LisdexamfetamineRemoxipride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Remoxipride.Approved
LofentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lofentanil.Illicit
LopinavirThe metabolism of Remoxipride can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remoxipride.Approved
LorcaserinThe metabolism of Remoxipride can be decreased when combined with Lorcaserin.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Remoxipride is combined with Lu AA21004.Investigational
LumefantrineThe metabolism of Remoxipride can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Remoxipride is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Melperone.Approved
MephedroneRemoxipride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineRemoxipride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride.Approved, Illicit
MequitazineRemoxipride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Metaxalone.Approved
MethadoneThe metabolism of Remoxipride can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineRemoxipride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methohexital.Approved
MethotrimeprazineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride.Approved, Investigational
MetoprololThe metabolism of Remoxipride can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineRemoxipride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Remoxipride.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Investigational
MirabegronThe metabolism of Remoxipride can be decreased when combined with Mirabegron.Approved
MirtazapineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDARemoxipride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride.Approved
MolindoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Remoxipride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Remoxipride.Approved, Withdrawn
NevirapineThe metabolism of Remoxipride can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Remoxipride can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Remoxipride can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Remoxipride is combined with Opium.Approved, Illicit
OrphenadrineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Remoxipride can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Remoxipride can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remoxipride.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
PerazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenoxyethanol.Approved
PhentermineRemoxipride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide.Approved
PramipexoleRemoxipride may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remoxipride.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Remoxipride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe metabolism of Remoxipride can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Remoxipride is combined with PSD502.Investigational
PseudoephedrineRemoxipride may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Remoxipride.Approved
QuinidineThe metabolism of Remoxipride can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Remoxipride can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Remoxipride can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Remoxipride.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ritanserin.Investigational
RitobegronRemoxipride may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Remoxipride can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Remoxipride.Approved
RolapitantThe metabolism of Remoxipride can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Romifidine.Vet Approved
RopiniroleRemoxipride may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride.Approved
RotigotineRemoxipride may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Remoxipride.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Remoxipride is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Remoxipride is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Remoxipride can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
StiripentolThe metabolism of Remoxipride can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Remoxipride.Approved, Investigational
SuvorexantRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Remoxipride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Remoxipride.Approved
TerbinafineThe metabolism of Remoxipride can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Remoxipride.Approved
TetracaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrodotoxin.Investigational
ThalidomideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Remoxipride can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiapride.Investigational
TiclopidineThe metabolism of Remoxipride can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiletamine.Vet Approved
TipranavirThe metabolism of Remoxipride can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Remoxipride can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Remoxipride is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Remoxipride.Approved, Investigational
VenlafaxineThe metabolism of Remoxipride can be decreased when combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Remoxipride.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Remoxipride can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Remoxipride.Approved, Investigational
ZolpidemRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US4232037
General ReferencesNot Available
External Links
ATC CodesN05AL04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9705
Caco-2 permeable+0.5835
P-glycoprotein substrateSubstrate0.775
P-glycoprotein inhibitor INon-inhibitor0.674
P-glycoprotein inhibitor IINon-inhibitor0.6462
Renal organic cation transporterNon-inhibitor0.5402
CYP450 2C9 substrateNon-substrate0.868
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5728
CYP450 1A2 substrateNon-inhibitor0.6776
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5505
Ames testNon AMES toxic0.6906
CarcinogenicityNon-carcinogens0.8373
BiodegradationNot ready biodegradable0.9703
Rat acute toxicity2.8267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.802
hERG inhibition (predictor II)Inhibitor0.7976
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility74 mg/LNot Available
logP2.10HOEGBERG,T ET AL. 1986
Predicted Properties
PropertyValueSource
Water Solubility0.127 mg/mLALOGPS
logP2.94ALOGPS
logP2.34ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.06ChemAxon
pKa (Strongest Basic)8.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.8 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity90.56 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylamides
Alternative Parents
Substituents
  • M-dimethoxybenzene
  • Dimethoxybenzene
  • 3-halobenzoic acid or derivatives
  • Salicylamide
  • Benzamide
  • Methoxybenzene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Halobenzene
  • Bromobenzene
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Aryl halide
  • Aryl bromide
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Lang AE, Sandor P, Duff J: Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. [PubMed:8665533 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Christian AJ, Goodwin AK, Baker LE: Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol Biochem Behav. 2001 Mar;68(3):371-7. [PubMed:11325388 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitt...
Gene Name:
SIGMAR1
Uniprot ID:
Q99720
Molecular Weight:
25127.52 Da
References
  1. Lang A, Soosaar A, Koks S, Volke V, Bourin M, Bradwejn J, Vasar E: Pharmacological comparison of antipsychotic drugs and sigma-antagonists in rodents. Pharmacol Toxicol. 1994 Sep-Oct;75(3-4):222-7. [PubMed:7800667 ]
  2. Okuyama S: [Atypical antipsychotic profiles of sigma receptor ligands]. Nihon Yakurigaku Zasshi. 1999 Jul;114(1):13-23. [PubMed:10562961 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23